Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#2114 Significance of Biochemical Testing in Pancreatic Neuroendocrine Tumors

Introduction: Pancreatic neuroendocrine tumors (PNETs) are rare tumors that are frequently diagnosed late in the course of the disease. Several biomarkers have been proposed in the literature for diagnosis in patients with these tumors.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Athar A,

Keywords: Biochemical markers, PNETs, Better prognosis,

#1857 Association between Neuroendocrine Tumors (NETs) Biomarkers and Tumor Burden Based on Total 68Ga-DOTATATE-Avid Tumor Volume (TV) Measurements

Introduction: No study has yet assessed the utility of biochemical biomarkers for evaluating NET burden using 68Ga-DOTATATE PET/CT.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author:

Authors: Tirosh A, Papadakis G, Millo C, Sadowski S, Herscovitch P,

Keywords: PET burden,

#1853 24 Hour Urinary 5-Hydroxyindoleacetic Acid (5HIAA) and Vasoactive Intestinal Peptide (VIP) Doubling-Times (DTs) Predict Disease-Specific Mortality (DSM) in Patients with Neuroendocrine Tumors (NETs)

Introduction: New clinical prognostic tools are needed in order to select patients with NETs that are at higher risk of DSM. Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Tirosh A

Authors: Tirosh A, Nilubol N, Patel D, Kebebew E,

Keywords: doubling time, biomarker, prognosis,

#899 Evaluation of the Clinical Utility of Plasma Biomarkers in Diagnosis of Neuroendocrine Tumors

Introduction: Neuroendocrine tumors (NETs) are rare cancers that usually develop in the gastroenterohepatic system. Diagnostic workup of these tumors includes measurement of plasma levels of marker peptides. Clinical experience suggests that these markers may be misleading if used before histological or imaging evidence of a NET is available.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Lunberg-Adams M

Authors: Lunberg-Adams M, James A, Perros P,

Keywords: chromogranin A, neurokinin A, pancreatic polypeptide, neuroendocrine tumor diagnosis,

#713 Non-Functioning Pancreatic Neuroendocrine Tumors (PNET): Association with Prediabetes/Diabetes

Introduction: Neuroendocrine tumors of pancreas (PNET) are classified as functional or nonfunctional (NF) based on presence or absence of clinical syndrome associated with hormone over secretion. NF-PNETs do, however, often produce low levels of inactive hormones (pancreatic polypeptide, calcitonin or neurotensin) which do not cause any symptoms.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Osher E

Authors: Osher E, Greenman Y, Tordjman K, Sofer Y, Scapa E,

Keywords: NF-PNET, DM/IFG,